ClinicalTrials.gg

Program

gadopiclenol

Also written as “P03277”, “Gadopiclenol” and “Elucirem”.

Its studies are mostly in Brain Neoplasms · Central Nervous System Diseases · Renal Insufficiency, led by Guerbet.

Furthest: phase 3, since Jun 11, 201912 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guerbet121 open or runningphase 3since Jun 11, 2019Dec 15, 2015Dec 31, 2027phase 3 · NCT07348640

Also a collaborator on its studies: bracco-imaging-s-p-a.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2015First study: phase 2 study in CNS LesionFirst studyNCT02633501 · 312 enrolled · United States, Belgium, Czechia and more
  2. Jul 16, 2018Phase 2 study in Healthy VolunteersNCT03603106 · 142 enrolled · Belgium
  3. Aug 31, 20182 phase 1 studiesNCT03657784, NCT03657264
  4. Nov 20, 2018Phase 2 study in Central Nervous System IndicationNCT03749252 · 80 enrolled · Bulgaria, Hungary, Poland and more
  5. Jun 11, 20192 phase 3 studiesNCT03986138, NCT03996447
  6. May 25, 2021Phase 1 study in PharmacokineticsNCT04906005 · 27 enrolled · Japan
  7. Oct 18, 2022Phase 2 study in Central Nervous System DiseasesNCT05590884 · 36 enrolled · United States, Hungary, Poland
  8. Jul 28, 2023Phase 3 study in Lesion in Body RegionNCT06010173 · 240 enrolled · Japan
  9. Sep 11, 2023Phase 3 study in Brain NeoplasmsNCT06057168 · 138 enrolled · Hungary, Italy, Poland
  10. Jan 15, 2026Phase 3 study in Steno-occlusive DiseaseNCT07348640 · 315 planned · United States, Canada, Czechia and more

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Steno-occlusive DiseaseNCT07348640

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07348640Steno-occlusive Disease · United States, Canada, Czechia and more3RecruitingDec 31, 2027315
NCT06057168Brain Neoplasms · Hungary, Italy, Poland3CompletedNov 28, 2024138
NCT06010173Lesion in Body Region · Japan3CompletedMay 6, 2025240
NCT05590884Central Nervous System Diseases · United States, Hungary, Poland2CompletedSep 30, 202436
NCT04906005Pharmacokinetics · Japan1CompletedJul 27, 202127
NCT03996447CNS Lesion · United States, Belgium, France and more3CompletedSep 11, 2020260
NCT03986138Lesion in Body Region · United States, Bulgaria, France and more3CompletedDec 9, 2020324
NCT03749252Central Nervous System Indication · Bulgaria, Hungary, Poland and more2CompletedDec 18, 201980
NCT03657784Renal Insufficiency · Moldova, Republic of, Romania1CompletedFeb 1, 201940
NCT03657264Healthy Volunteers · Belgium1CompletedJun 7, 201848
NCT03603106Healthy Volunteers · Belgium2CompletedApr 17, 2015142
NCT02633501CNS Lesion · United States, Belgium, Czechia and more2CompletedJan 2018312

How it is read

Names in the registry

  • “gadopiclenol”, 4 entries
  • “P03277”, 4 entries
  • “Gadopiclenol”, 2 entries
  • “Elucirem”, 1 entry
  • “P03277 0.1 mmol/kg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.